Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dhiraj Gadekar

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Zhongguo Ying Yong Sheng Li Xue Za Zhi = Zhongguo Yingyong Shenglixue Zazhi = Chinese Journal of Applied Physiology|February 24, 2026
Sunvozertinib A Next-Generation EGFR Exon 20 Insertion Inhibitor Transforming NSCLC TherapyManoj Kumbhare, Dhiraj Gadekar, Siddhi Chandak, et al.
Zhongguo Ying Yong Sheng Li Xue Za Zhi = Zhongguo Yingyong Shenglixue Zazhi = Chinese Journal of Applied Physiology|December 9, 2025
Next-Generation Targeted Therapy: The Evolving Role of Taletrectinib in Fusion-Positive MalignanciesSamiksha Mankar, Manoj Kumbhare, Siddhi Chandak, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Zhongguo Ying Yong Sheng Li Xue Za Zhi = Zhongguo Yingyong Shenglixue Zazhi = Chinese Journal of Applied Physiology|February 24, 2026
Sunvozertinib A Next-Generation EGFR Exon 20 Insertion Inhibitor Transforming NSCLC TherapyManoj Kumbhare, Dhiraj Gadekar, Siddhi Chandak, et al.
Zhongguo Ying Yong Sheng Li Xue Za Zhi = Zhongguo Yingyong Shenglixue Zazhi = Chinese Journal of Applied Physiology|December 9, 2025
Next-Generation Targeted Therapy: The Evolving Role of Taletrectinib in Fusion-Positive MalignanciesSamiksha Mankar, Manoj Kumbhare, Siddhi Chandak, et al.
Pageof 1